Statements (11)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
stock ticker
|
| gptkbp:focusesOn |
ear, nose, and throat (ENT) disorders
|
| gptkbp:formerName |
gptkb:Tokai_Pharmaceuticals,_Inc.
|
| gptkbp:headquartersLocation |
Irvine, California, United States
|
| https://www.w3.org/2000/01/rdf-schema#label |
NVUS
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:listedOn |
gptkb:NASDAQ
|
| gptkbp:refersTo |
gptkb:Novus_Therapeutics,_Inc.
|
| gptkbp:website |
https://www.novustherapeutics.com/
|
| gptkbp:bfsParent |
gptkb:Novus_Therapeutics
|
| gptkbp:bfsLayer |
7
|